AKT1 and T-cell non-Hodgkin lymphoma: Combination targeting of the PI3K/Akt/mTOR signaling pathway appears to be more effective due to the activation of alternative signaling pathways by negative feedback, with drug sensitivity profiling revealing that inhibition of both mTOR and JAK may be more effective than single agents in NK/T-cell lymphoma cell lines [77].